

Having trouble finding Revumenib (Revuforj) in stock? Here are 3 proven tips and tools to help you locate this specialty leukemia medication in 2026.
You've been diagnosed with relapsed or refractory acute leukemia. Your doctor has prescribed Revumenib (brand name Revuforj), a first-in-class menin inhibitor that could make a real difference in your treatment. But now you're facing a frustrating problem: actually finding it.
Revumenib isn't available at your typical pharmacy. It's a specialty oncology medication distributed through a limited network of pharmacies, and that can make tracking it down feel like a second job — one you didn't sign up for.
The good news? There are tools and strategies that can help. Here are three practical tips for finding Revumenib in stock near you in 2026.
One of the fastest ways to find out where Revumenib is available is to use Medfinder. Medfinder helps patients search for medications across pharmacies and can show you which specialty pharmacies near you have Revuforj in stock or can order it.
Instead of spending hours on the phone calling pharmacy after pharmacy, Medfinder lets you search in one place. This is especially helpful for specialty drugs like Revumenib that aren't widely stocked.
Even if a pharmacy doesn't have Revumenib on the shelf right now, they may be able to order it for you within a few days. Medfinder can help you identify which ones to call.
Your oncologist's office is your most valuable resource in getting Revumenib. Hematology-oncology practices work with specialty pharmacies every day and often have dedicated staff to handle prior authorizations and specialty drug orders.
Additionally, Syndax Pharmaceuticals offers a support program called SyndAccess specifically for Revuforj patients. SyndAccess provides:
Contact SyndAccess at 1-888-567-SYND (7963), Monday through Friday, 8 AM to 8 PM ET.
Don't wait until you've run out of options to call. Reaching out to SyndAccess early — ideally when your doctor first writes the prescription — can cut days or weeks off the process.
With specialty medications like Revumenib, timing matters. Here are some practical steps to avoid delays:
The process can feel frustrating, but persistence pays off. Most patients who stay on top of their orders get their medication filled within a reasonable timeframe.
If you've tried everything above and you're still hitting walls, consider these additional options:
Some specialty pharmacies and manufacturer programs offer bridge supply or emergency doses while your prior authorization is being processed. Ask your oncologist or SyndAccess if this is available for Revuforj.
If Revumenib is unavailable or there are long delays, your oncologist may consider other treatment options. While Revumenib is the only FDA-approved menin inhibitor, other treatments for relapsed/refractory acute leukemia exist. For more information, read our article on alternatives to Revumenib.
Sometimes calling your insurance company's specialty pharmacy helpline can speed things up. Ask specifically about the status of your prior authorization and whether they have a preferred specialty pharmacy for Revuforj.
Finding Revumenib in 2026 requires more effort than picking up a typical prescription, but it's doable with the right approach. Use Medfinder to check availability, lean on your oncology team and SyndAccess for support, and be proactive about starting the process early.
You're dealing with enough already — your medication shouldn't be one more thing that keeps you up at night. With persistence and the right tools, you can get the treatment you need.
For more information about Revumenib, including dosage, side effects, and drug interactions, explore our other guides:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.